Inhibitors of HCV NS5A

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9120779
APP PUB NO 20110237579A1
SERIAL NO

13132606

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention relates to non-macrocyclic, non-peptidic, substituted heterocyclic compounds useful for inhibiting hepatitis C virus (“HCV”) replication, particularly functions of the non-structural 5A (“NS5A”) protein of HCV.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
PRESIDIO PHARMACEUTICALS INC1700 OWENS STREET SUITE 585 SAN FRANCISCO CA 94158

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Li, Leping San Francisco, US 119 2017
Zhong, Min San Francisco, US 113 878

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Mar 1, 2027
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00